Finanztrends
Deine Einschätzung
Was spricht für und gegen Advanced Proteome Therapeutics in den nächsten Jahren?
Pro
?
L*********** I********** f** d** n******* J****
?
M****
?
M************
Kontra
?
A****************
?
W******* i* V********
?
U****************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Advanced Proteome Therapeutics im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -1,12 % | 5,45 % | 10,13 % | 14,47 % | 4,82 % | -3,33 % | -60,90 % |
| Northwest Biotherapeutics Inc. | 0,00 % | -2,99 % | -18,75 % | -31,58 % | -36,89 % | -70,72 % | -87,85 % |
| Achieve Life Sciences Inc. | 0,89 % | 5,56 % | 0,88 % | 160,87 % | 54,05 % | 17,28 % | -7,32 % |
News
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer
ROCKVILLE, MD /ACCESS Newswire/ August 10, 2026 / ABL Inc and Ascend Advanced Therapiestoday announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further
ABL Ascend Advanced Therapies ernennt Suman Subramanian zum Chief Business Officer
ROCKVILLE, MD / ACCESS Newswire / 10. August 2026 / ABL Inc. und Ascend Advanced Therapies gaben heute die Ernennung von Suman Subramanian zum Chief Business Officer (CBO) bekannt. Damit
Lundin Mining Q2 Earnings Call Highlights
Key Points
- Interested in Lundin Mining Co.? Here are five stocks we like better.
- Lundin Mining delivered strong Q2 results, with revenue above $1.2 billion, adjusted EBITDA of $658 million and
